title: [The role of 5-HT3, 5-HT(1A) receptors and its coaction in the regulation behavior in mice].
abstract: Here we investigated whether the 5-HT3 receptor and the 5-HT3/5-HT(1A) receptors coaction play essential role in the regulation of locomotion, depressive-like and social behavior. It was found that central administration of selective agonist of 5-HT3 receptor m-CPBG (2.5, 5.0, 10.0 nmol) produced significant decrease of horizontal and vertical locomotor activity in the open field (OF) test. Selective antagonist of 5-HT(1A) receptor WAY-100635 (2.0 mg/kg (3.7 μmol/kg), i.p.) attenuated the effect of m-CPBG on behavior in the OF test. Selective 5-HT(1A) receptor agonist 8-OH-DPAT (0.25, 0.5, 1.0 mg/kg (0.76, 1.5 and 3.0 μmol/kg correspondingly), i.p.) significantly decreased horizontal and vertical locomotor activity in the OF test as well. The activation of 5-HT3 receptors failed to affect immobility time in the tail suspension test, whereas the activation 5-HT(1A) receptors significantly decreased the immobility time. Administration of m-CPBG also did not produced considerable effect on social behavior. At the same time, 8-OH-DPAT significantly decreased time and number of social contacts. Thus it was shown for the first time that 5-HT3 receptor-induced behavioral response observed in the OF realized mainly via 5-MHT(1A) receptor. Obtained results provide new evidence on the role of 5-HT3 receptors and 5-HT3/5-HT(1A) receptors coaction in the regulation of locomotor activity but not in the depressive-like and social behavior.
authors.forename: E M
authors.initials: EM
authors.lastname: Kondaurova
authors.forename: V S
authors.initials: VS
authors.lastname: Naumenko
authors.forename: D B
authors.initials: DB
authors.lastname: Bazovkina
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000818:Animals; D001645:Biguanides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D020239:Receptor Cross-Talk / Q000502:physiology*; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism*; D058827:Serotonin 5-HT3 Receptor Agonists / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D012919:Social Behavior
chemical_list: D001645:Biguanides; D010879:Piperazines; D011725:Pyridines; D044406:Receptors, Serotonin, 5-HT3; D058827:Serotonin 5-HT3 Receptor Agonists; D012702:Serotonin Antagonists; D044282:Receptor, Serotonin, 5-HT1A; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C065734:1-(3-chlorophenyl)biguanide